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Abstract
Juvenile idiopathic arthritis (JIA) is the most common cause of
chronic childhood disability and encompasses a number of
disease subgroups. In this study we have focused on systemic
JIA (sJIA), which accounts for approximately 11% of UK JIA
cases. This study reports the investigation of three members of
the IL10 gene family as candidate susceptibility loci in children
with sJIA. DNA from 473 unaffected controls and 172 patients
with sJIA was genotyped for a single nucleotide polymorphism
(SNP) in IL19 and IL20 and two SNPs in IL10. We examined
evidence for association of the four SNPs by single marker and
haplotype analysis. Significant differences in allele frequency
were observed between cases and controls, for both IL10-1082
(p = 0.031) and IL20-468 (p = 0.028). Furthermore,
examination of the haplotypes of IL10-1082 and IL20-468
revealed greater evidence for association (global p = 0.0006).
This study demonstrates a significant increased prevalence of
the low expressing IL10-1082 genotype in patients with sJIA. In
addition, we show a separate association with an IL20
polymorphism, and the IL10-1082A/IL20-468T haplotype. The
two marker 'A-T' haplotype confers an odds ratio of 2.24 for
sJIA. This positive association suggests an important role for
these cytokines in sJIA pathogenesis.
Introduction
Juvenile idiopathic arthritis (JIA) is the most common cause of
childhood disability, with an incidence of 1 in 10 000 children
under the age of 16 [1]. It is a clinically heterogeneous group
of complex diseases, with polygenic and environmental factors
all playing a role in aetiology. There are seven clinically distinct
subtypes of JIA [2]. The most severe and least responsive to
current therapies is systemic JIA (sJIA), a disease defined by a
quotidian fever and one or more manifestations, including an
evanescent rash, lymphadenopathy, hepatomegaly or
splenomegaly, or serositis. While HLA associations are a sig-
nificant genetic factor in other JIA subtypes, there are no asso-
ciations with Caucasian sJIA [3]. However, a number of non-
HLA genes have been reported to be associated with sJIA,
including those encoding IL6 and Macrophage inhibitory fac-
tor [4,5].
IL10 is a cytokine with potent immunoregulatory and anti-
inflammatory properties. It acts to suppress the release and
function of a number of pro-inflammatory cytokines, including
IL1, tumour necrosis factor (TNF)-α, and IL6 [6]. Low levels of
IL10 production associated with autoimmune disease, such as
rheumatoid arthritis, psoriasis, and collagen-induced arthritis,
suggest defective regulatory roles of IL10 in limiting inflamma-
tion and reversing immunopathology. However, IL10 is also a
stimulatory factor for mast cells, B cells, and thymocytes [7,8].
In the upstream regulatory region of the gene encoding IL10,
the three most characterised single nucleotide polymorphisms
(SNPs) are at positions -1,082 (G to A), -819 (C to T) and -
592 (C to A) [9,10]. There is absolute linkage disequilibrium
(LD) between the IL10-819 and IL10-592 SNPs. In the Cau-
casian populations only three out of the remaining four possi-
ble haplotypes occur: GCC, ACC and ATA. We have
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previously shown that stimulation of human whole blood cul-
tures with bacterial lipopolysaccharide (LPS) results in a large
variation between individuals in IL10 secretion. When exam-
ined in the context of IL10 genotype, it was revealed that the
ATA/ATA genotype is associated with significantly lower IL10
production [11,12]. In addition, we also showed a significantly
increased frequency of this low-expressing ATA haplotype in
extended juvenile oligoarthritis. There is strong evidence to
support genetic control of IL10 levels, with production levels
showing concordance in monozygotic twins and a genetic
component of over 75% [13]. Turner and colleagues [9] dem-
onstrated that the difference in IL10 secretion is associated
with the presence or absence of an 'A' at position -1,082 of
the human IL10 promoter.
In the severe forms of JIA, treatment is often limited to high
doses of glucocorticoids. It is of interest, therefore, that pre-
treatment with IL10 improves the ability of dexamethasone in
suppressing IL6 (a cytokine correlated with sJIA disease activ-
ity) in whole-blood cultures (p < 0.01) [14]. Furthermore, LPS-
stimulated whole blood cultures from sJIA patients showed
reduced levels of IL10 compared to healthy, age matched con-
trols [11]. This reduced capacity of sJIA patients to produce
sufficient quantities of this anti-inflammatory cytokine may sug-
gest a pathogenic role for IL10 in this disease.
Two recently described members of the IL10 family are IL19
and IL20. The genes encoding these cytokines are located
within a highly conserved cytokine gene cluster in 1q32. Like
the T-Helper 2 (TH2) IL4 cytokine gene cluster, recent evi-
dence from the mouse IL10 gene family cluster suggests that
there is coordinate regulation of these cytokines by distal reg-
ulatory elements spanning the locus [15]. Both IL19 and IL20
are produced by a diverse range of cell types, including mono-
cyte/macrophages, T- cells and keratinocytes [16]. Interest-
ingly, long-term exposure of T cells to IL19 and IL20 down-
regulated interferon-γ but up-regulated IL4 and IL13 and sup-
ported the polarisation of naive T cells to Th2-like cells [17].
Apart from significant genetic association of Hepatitis C virus
clearance with IL10/19 and IL20, and psoriasis with IL19/20
and IL24, to our knowledge no additional disease association
studies with these cytokine genes have been conducted
[18,19].
The IL10 SNPs are located 592 base-pairs (bp) and 1,082 bp
upstream of the IL10 transcription start site. The non-synony-
mous SNP in IL19 and a SNP in IL20 are situated further
upstream at 70 kb and 93 kb, respectively, relative to the tran-
scription start of IL10. These SNPs are all potentially func-
tional polymorphisms and were chosen as representatives
from this region of the cytokine cluster for association analysis
with sJIA. SNPs with a minor allele frequency >0.10 were
selected to increase the power to detect an association. This
is the first association analysis of members of the IL10 gene
family to be performed in sJIA.
Materials and methods
Patients and control sample collection
Patients' DNA from the British Paediatric Rheumatology
Group (BPRG) National DNA repository held at the Arthritis
Research Campaign (ARC) Epidemiology Unit, Manchester,
was used for genotyping the markers across the IL10, IL19
and IL20 loci. Additional patients were also recruited from the
Outpatient Departments at both Great Ormond Street Hospi-
tal and the Middlesex Hospital. Ethical approval for the study
was obtained and parents gave informed consent. Two ethni-
cally matched healthy control populations were used for this
case/control study. One population was composed of first
time blood donors attending the national blood transfusion
centre in London (n = 248). The second population was col-
lected from individuals in the 16 to 30 years age group from a
GP practice in a stable population of the west Midlands (n =
225).
Genotyping
DNA from 172 patients with sJIA and 473 unaffected controls
was genotyped for the IL19+13735 (rs2243191) and IL20-
468 (rs1400986) SNPs, and two previously characterized
SNPs in IL10, IL10-592 (rs1800872) and IL10-1082
(rs1800896).
Pyrosequencing was used to genotype the polymorphisms in
IL10. A fragment 50 to 200 bp flanking the SNP was PCR
amplified. The anti-sense primer was biotinylated to allow the
preparation of single-stranded DNA. An aliquot of 25 ng of
DNA was amplified in a 25 µl PCR reaction with 0.25 µM of
each primer, 0.2 mM of each of the four dNTPs, 0.5 U of Taq
polymerase (Promega, Madison WI USA), 2.5 mM of MgCl2
and 1× KCl buffer. The cycling parameters consisted of an ini-
tial denaturation at 94°C for 5 minutes and then 35 cycles of
30 s denaturation at 94°C, 30 s annealing at 67°C and 11 s
extension at 72°C. A final extension step was carried out for 7
minutes at 72°C. We immobilized 10 µl of the PCR product on
streptavidin sepharose beads (GE Healthcare, Uppsala, Swe-
den) and the pyrosequencing was performed according to the
standard PSQ HS 96A system protocol (Pyrosequencing AB,
Uppsala, Sweden).
Genotyping of the SNPs in the genes encoding IL19 and IL20
was carried out using Sequenom MassARRAY, (San Diego,
CA, USA). Primers designed by RealSNP assay (Sequenom)
amplified approximately 100 bp of sequence surrounding the
target SNP. PCR was carried out using 1× HotStar Taq PCR
buffer 2.5 mM MgCl2 (Qiagen, Crawley, West Sussex, UK),
500 µM of each dNTP, 0.1 U Enzyme HotStar Taq polymerase
(Qiagen), 100 nM primer, and 2.5 ng of genomic DNA in a
total volume of 5 µl. PCR was followed by incubation with
shrimp alkaline phosphatase to digest unincorporated dNTPs
and primers. This product was used to carry out MassExtend
reactions using flanking extend primers, dideonucleotides and
Taq polymerase to extend the primer through the polymorphicAvailable online http://arthritis-research.com/content/8/5/R148
Page 3 of 5
(page number not for citation purposes)
site. Finally, the extended product was purified of excess ions
using an ion-exchange resin. Genotypes were acquired using
a chip-based matrix-assisted laser desorption ionization-time-
of-flight (MALDI-TOF) mass spectrometer.
Association analysis
Tests for Hardy-Weinberg equilibrium and for single locus
association were performed using chi-squared statistics. Hap-
loview was used to assess the level of LD between markers
across this region by analysing control genotypes only [20].
We examined evidence for association of the four SNPs by
single marker and haplotype analysis using Cocaphase soft-
ware (UNPHASED) [21]. The p values have not been cor-
rected for multiple testing since each SNP had a strong prior
hypothesis for testing for association with systemic JIA.
Results
Linkage disequilibrium analysis
Analysis of LD across these markers confirms previous reports
of an intermediate level of LD between IL10-1082 and IL10-
592 within the IL10 promoter region (data not shown). No LD
was observed between the IL10 markers and either
IL19+13735 or IL20-468 SNPs, or between IL19+13735
and IL20-468. LD patterns using r2 were similar in the cases
(Figure 1).
Association analysis
All SNPs were in Hardy-Weinberg equilibrium in cases and
controls. Significant differences in allele frequency were
observed between sJIA cases and controls for IL10-1082 (p
= 0.031). The association was not, however, due to the ATA
haplotype, as no further genotype or haplotype effects were
observed with IL10-592. Significant differences in allele fre-
quency were also observed for the IL20 marker IL20-468 (p =
0.028; Table 1). When the two associated markers were
examined as a haplotype there was an increased level of sig-
nificance in association with disease (global p = 0.0006).
Analysis of the haplotype frequencies revealed a decrease of
the common haplotype in the cases, along with an increase in
the carriage of the rare haplotype containing the low express-
ing 'A' allele variant of IL10-1082 and the rare 'T' allele of IL20-
468 (Table 2).
There was no evidence of interaction between these SNPs.
Each copy of IL10-1082A confers an increased risk of 1.3 of
developing sJIA, and each copy of IL20-468T confers a risk of
1.507, with a combined risk of 2.24 across both SNPs.
The IL10-592 SNP and IL19+13735 SNPs show no signifi-
cant association with sJIA.
Figure 1
Pairwise linkage disequilibrium (r2) for the four markers tested in the  genes encoding IL10, IL19 and IL20 Pairwise linkage disequilibrium (r2) for the four markers tested in the 
genes encoding IL10, IL19 and IL20. The rs numbers refer to SNPs 
IL10-1082 (rs1800896), IL10-592 (rs1800872), IL19+13735 
(rs2243191) and IL20-468 (rs1400986).
Table 1
Single marker analyses of association in systemic juvenile idiopathic arthritis
Marker Case Control Odds ratio p value
Allele 1 Allele 2 Allele 1 Allele 2
IL10-1082G/A (allele 1 = G; allele 2 = A) 139 (0.45) 169 (0.55) 425 (0.52) 387 (0.48) 1.335 0.031
IL10-592C/A (allele 1 = C; allele 2 = A) 222 (0.71) 92 (0.29) 647 (0.76) 205 (0.24) 1.308 NS
IL19+13735C/T (allele 1 = C; allele 2 = T) 188 (0.77) 56 (0.23) 692 (0.78) 194 (0.22) 1.063 NS
IL20-468C/T (allele 1 = C; allele 2 = T) 189 (0.79) 51 (0.21) 765 (0.85) 137 (0.15) 1.507 0.028
The numbers in the table represent the typed alleles for IL10-1082, IL10-592, IL19+13735 and IL20-468; the frequencies are in parentheses. 
NS, non-significant.Arthritis Research & Therapy    Vol 8 No 5    Fife et al.
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Discussion
A feature common to all subgroups of JIA is chronic inflamma-
tion and synovitis. Cytokines are important regulators of inflam-
mation and many studies have shown persistent cytokine
imbalance in JIA [12,22,23]. Ourselves and others have previ-
ously shown that IL6 levels in the serum and synovial fluid of
sJIA patients are elevated and appear to correlate with disease
activity [4,24]. Furthermore, we have replicated the case/con-
trol association study of this locus with sJIA, using the trans-
mission disequilibrium test, confirming its role in disease
susceptibility [25]. The haplotypic structure of the IL6 locus
was extensively examined and we showed that a four marker
haplotype has greater power in demonstrating association
with sJIA susceptibility [26]. As IL10 suppresses the release
of pro-inflammatory cytokines such as IL6 and TNFα, it is a
normal endogenous feedback factor for the control of inflam-
mation. Having previously identified IL10 as a marker for
another severe form of JIA, extended oligoarthritis, here we aim
to broaden the analysis to the IL10 gene family in sJIA using
haplotype analysis.
In this study we have shown a significant increased prevalence
of the IL10-1082 A allele, associated with low IL10 produc-
tion, in patients with sJIA. In addition, we have also shown a
separate association with another member of the IL10 gene
family: IL20. The significant association of the low expressing
IL10 allele with sJIA implies that the regulation of pro-inflam-
matory cytokine production in multiple cell types, as well as the
regulation of CD4+ cells, may be suboptimal. Interaction of
IL10 with other cytokines in antigen presentation and T cell
polarisation pathways could determine the phenotype of the
disease. For example, decreased levels of IL10 concomitant
with increased IL6 would tend to favour the development of
Th2 T helper cells as well as preventing the differentiation of
regulatory T cells (T regs) in some instances. Our earlier study
of whole blood cultures of systemic JIA has shown that there
is no spontaneous production of cytokines but that there may
be an inadequate IL10 response to LPS stimulation compared
to that of controls [11]. IL10 is produced by some T regs gen-
erated in the periphery (Tr1) in humans, as well as by regula-
tory B cells in animal models [27]. T regs have been found to
increase after autologous stem cell transplantation and dis-
ease remission in sJIA [28]. Thus, there is a suggestion from
these preliminary observations that the numbers of T regs are
suboptimal in sJIA, and this may also play a role in the
decreased IL10 levels in these patients.
Recent evidence indicates that IL19 may also play a central
role in inflammation as it up-regulates monocyte derived IL6
and TNFα in mice [29]. Like IL20, IL19 is also associated with
psoriasis, another inflammatory disease [18]. Although we
show no evidence for association of IL19 in this study, it can-
not be eliminated as a candidate gene for sJIA. An in-depth
tagging SNP approach to refute or confirm any associations in
this region is currently being planned.
The increased significance of the association with the IL10-
1082/IL20-468 haplotype relative to the single markers may
indicate a functional role of the compound haplotype in dis-
ease susceptibility. Alternatively, it could be that neither the
IL10 nor the IL20 markers are sJIA susceptibility loci, but
merely in strong LD with an as yet uncharacterised functional
polymorphism. There has only been limited analysis of the reg-
ulation and expression of the cluster of IL10-like genes at this
locus, but this does point to a coordinated expression of these
genes. Jones and Flavell [15] identified three enhancer ele-
ments in a 40 kb region between the genes encoding IL19 and
IL10. Two of these enhancer elements, located 9 kb upstream
and 6.45 kb downstream of the gene encoding IL10, display
cell-specific function and also exhibit basic promoter activity.
Hence, any polymorphism within these novel regulatory ele-
ments may alter the function or expression of any intermediate
regulatory RNAs. The association we observe for the IL10-
1082/IL20-468 haplotype may be attributable to any one of
these regulatory regions carried on this haplotype.
Due to the low prevalence of sJIA, the number of cases used
in this study is restricted. To compensate for the limited case
collection, we have used a control :case ratio of 2.75 to
increase the power of the study. Additional patient samples
will be needed to confirm this finding in a replication study.
Conclusion
This study describes a new association between the two IL10
gene family members and children with sJIA, indicative of a
central role for these cytokines in disease pathogenesis.
Table 2
Haplotype analysis results for association in systemic juvenile idiopathic arthritis
Haplotype (IL10-1082/IL20-468) Cases Controls Chi square p value
-1082G/-468C 118.3 (0.36) 428.4 (0.46) 10.09 0.0015
-1082G/-468T 34.2 (0.10) 70.7 (0.08) 2.431 NS
-1082A/-468C 132.3 (0.40) 364.6 (0.39) 0.2943 NS
-1082A/-468T 47.2 (0.14) 76.29 (0.08) 12.57 0.0004
The numbers in the table represent the expected number of haplotypes, inferring missing genotype data from haplotype frequencies and linkage 
disequilibrium. Haplotype frequencies shown in parentheses. Global significance p = 0.0006. NS, non significant.Available online http://arthritis-research.com/content/8/5/R148
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